Skip to content

Studying Cognitive Outcome of Renal Transplantation with a Kidney of a Live Donor

Studying Cognitive Outcome of Renal Transplantation with a Kidney of a Live Donor - SCORE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41620
Enrollment
62
Registered
2013-10-14
Start date
2013-10-30
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

executive tasks and/or information processing functioning of memory language

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients undergoing a scheduled renal transplantation with a live kidney donor before having started dialysis or within one year after starting dialysis and their donors. * Sufficient visual and hearing acuity * Dutch or English language fluency * Willingness to give informed consent * ABO compatible

Exclusion criteria

Exclusion criteria: * Pre-existing documented cognitive impairment * A history of psychiatric illness * Use of psychoactive substances * A history of cerebrovascular disease (either transitory ischaemic attack or cerebrovascular accident) * Brain injury * Epilepsy * Acute or chronic infections * Malignancy * Unstable coronary vascular disease * Uncontrolled hypertension * Liver disease or other metabolic disease leading to encephalopathy * Diabetes mellitus * Uncorrected anemia (Hb

Design outcomes

Primary

MeasureTime frame
The change in mental performance in kidney recipients at twelve months after transplantation compared to pre-transplantation.

Secondary

MeasureTime frame
o The change in mental performance in kidney recipients at twelve months after transplantation compared to the change in mental performance in kidney donors. o Changes in cortical, hippocampal, temporal atrophy and global cerebral atrophy, using both visual rating scales as well as volumetric analyses. o Changes in white matter lesions using both visual rating scales as well as volumetric analyses. o Presence of microinfarctions and areas with microbleeding at baseline and occurrence of new lesions during followup. o Change in cerebral blood flow as measured by arterial spin labelling.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)